Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
Key Highlights
- ➤ORIGIN 3 final efficacy analysis of TRUTAKNA (VERA) will headline ASN Kidney Week’s opening plenary session
- ➤PIONEER interim adult IgAN and pMN results will receive a late-breaking oral presentation
- ➤Five Vera-sponsored abstracts will be presented at ASN Kidney Week 2026
- ➤TRUTAKNA indication reduces proteinuria in adults with IgAN at risk for progression
Expert Statements
Jonathan Barratt, Mayer Professor of Renal Medicine, University of Leicester
“The ORIGIN 3 Trial of Atacicept in IgA Nephropathy”
Richard Lafayette, Professor of Medicine (Nephrology) and Director of the Glomerular Disease Center at Stanford University Medical Center
“Interim Results from the Adult IgAN and Primary Membranous Nephropathy (pMN) Cohorts in the Atacicept PIONEER Trial”
Howard Trachtman, University of Michigan
“The PIONEER Trial: Expanding Evaluation of Atacicept, a B-Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) Inhibitor, to Pediatric Patients with IgAN”
Damemarie Paul, DrPH, MPH, Vera Therapeutics
“Rapid Progression in IgAN Despite Treatment: Real-World Evidence of Suboptimal Disease Control in the United States”
Navdeep Tangri, MD, University of Manitoba
“Aurora: A Multi-Site Clinical Implementation Network for IgA Nephropathy”
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy (IgAN) will be a featured late-breaking oral presentation during the opening plenary session and also a late-breaking research poster. In addition, interim results from the adult IgAN and primary membranous nephropathy (pMN) cohorts in PIONEER, a Phase 2 basket trial of atacicept in multiple glomerular diseases, will be a late-breaking research oral presentation. In total, five Vera sponsored abstracts will be presented at ASN Kidney Week 2026, demonstrating the Company’s commitment to transforming medicine in autoimmune kidney disease.
Get started
Create a free account to read the full story.